Global Neutropenia Treatment Market 2017-2021

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

PART 03: Research Methodology

PART 04: Introduction

• Key market highlights

PART 05: Disease overview

• Neutropenia

PART 06: Key clinical trials

PART 07: Market landscape

• Market overview
• Five forces analysis

PART 08: Market segmentation  by drug class

• G-CSF treatment market
• Antibiotics treatment market
• Antifungal drugs treatment market
• Others
• Geographical segmentation
• Neutropenia market in Americas
• Neutropenia market in EMEA
• Neutropenia market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

• Market drivers
• Market challenges
• Impact of drivers and challenges on key customer segments (pharmacy and hospitals)

PART 11: Market trends

• Evolving payer’s interest toward G-CSF biosimilars
• Paradigm shift in management of febrile neutropenia
• Advent of small molecules

PART 12: Vendor landscape

• Competitive scenario

PART 13: Key vendor analysis

• Amgen
• Novartis
• Teva Pharmaceutical
• Other prominent vendors

PART 14: Appendix

• List of abbreviations